-
Lessons Learnt From PICO Exercise Developed by the Joint Clinical Assessment Subgroup for Etranacogene Dezaparvovec
Sep 9, 2025, 16:22 PM -
Uncertainties in Regulatory Benefit-Risk Decision Making for Innovative Anticancer Therapies: Preliminary Results From a 2011-2024 Review of Extensions of Indications
Sep 9, 2025, 16:22 PM -
From Admission to Discharge: Understanding the Transplant Patient Journey With German Statutory Health Insurance Claims Data
Sep 9, 2025, 16:22 PM -
A Conceptual Paper on Integrating a Pharmacometric Multistate Model With Cost-Effectiveness Analysis for Infectious Diseases Treatment Optimization
Sep 9, 2025, 16:22 PM -
Development of a Unique Tool for Assessing the Feasibility of an External Control Arm Study
Sep 9, 2025, 16:22 PM -
Challenges in the German AMNOG Procedure: The Need for National PICO Transparency and Optimized Consultation Windows in the Context of EU-HTA
Sep 9, 2025, 16:22 PM -
Italian Perspective on Rare Disease New Treatments and HTA: Insights From Iptacopan Multidimensional Evaluation in PNH
Sep 9, 2025, 16:22 PM -
Validation Between Antidepressant Treatment Failure Proxy and PHQ-9 Score in Major Depressive Disorder Using a Linked Insurance Claims and Electronic Health Record Dataset
Sep 9, 2025, 16:22 PM -
Healthcare Resource Use and Direct Healthcare Costs Associated With Respiratory Syncytial Virus Infections in Individuals Aged 18 Years or Older in Italy: A Retrospective Observational Study
Sep 9, 2025, 16:22 PM -
Trends in the Number of Hospital Beds and Patient Turnover in Obstetrics and Gynecology in Hungary Between 2003 and 2023
Sep 9, 2025, 16:22 PM -
Natural Language Processing for Identification of Negative Symptoms in Patients With and Without Cognitive Impairment Associated With Schizophrenia (CIAS)
Sep 9, 2025, 16:22 PM -
Country-Specific Adaptation of Health Economic Models With Generative AI: A Case Study in Alzheimer’s Disease
Sep 9, 2025, 16:22 PM -
Cost Trends for Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) Management in Relapsed/Refractory Large B-cell Lymphoma (R/R LBCL) Treatment With Axicabtagene Ciloleucel (Axi-cel) in the US
Sep 9, 2025, 16:22 PM -
Optimizing Patient-Reported Outcomes in German HTA: Addressing Key Challenges and Methodological Requirements
Sep 9, 2025, 16:22 PM -
Evaluating Clinical Similarity: A Systematic Review of Methods Used Within National Institute for Health and Care Excellence (NICE) Cost-Comparison Evaluations (CCEs) When Relying on Statistically Nonsignificant Differences From Indirect Treatment...
Sep 9, 2025, 16:22 PM -
HTA League of Nations: Which Bodies Were Most Likely to Approve Submissions and for What Disease Areas?
Sep 9, 2025, 16:22 PM -
Care Partner Burden and Experiences With Schizophrenia: A National Canadian Survey
Sep 9, 2025, 16:22 PM -
Incentivizing Access to New Drugs in Psychiatry: Exploration of a Subscription Payment Approach to Overcome Barriers to European Launch
Sep 9, 2025, 16:22 PM -
Economic Impact of Emicizumab vs. On-Demand Therapy With Bypassing Agents in Patients With Hemophilia A With Inhibitors in Mexico
Sep 9, 2025, 16:22 PM -
Development and Validation of a Case Identification Algorithm for Hand Trauma Patients Using Health Administrative Data and the Epidemiology of Hand Trauma in a Universal Healthcare System
Sep 9, 2025, 16:22 PM
